GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Net Current Asset Value

Cutia Therapeutics (HKSE:02487) Net Current Asset Value : HK$4.70 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Cutia Therapeutics's net current asset value per share for the quarter that ended in Jun. 2023 was HK$4.70.

The historical rank and industry rank for Cutia Therapeutics's Net Current Asset Value or its related term are showing as below:

HKSE:02487' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.42   Med: 5.21   Max: 5.21
Current: 1.71

During the past 3 years, the highest Price-to-Net-Current-Asset-Value Ratio of Cutia Therapeutics was 5.21. The lowest was 1.42. And the median was 5.21.

HKSE:02487's Price-to-Net-Current-Asset-Value is ranked better than
77.55% of 1029 companies
in the Biotechnology industry
Industry Median: 3.96 vs HKSE:02487: 1.71

Cutia Therapeutics Net Current Asset Value Historical Data

The historical data trend for Cutia Therapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Net Current Asset Value Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Net Current Asset Value
-3.56 -5.68 5.66

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value -3.56 - -5.68 4.70 3.79

Competitive Comparison of Cutia Therapeutics's Net Current Asset Value

For the Biotechnology subindustry, Cutia Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's Price-to-Net-Current-Asset-Value falls into.



Cutia Therapeutics Net Current Asset Value Calculation

Cutia Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1279.113-3007.448-0-0)/304.024
=-5.68

Cutia Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2023 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1618.835-188.604-0-0)/304.024
=4.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cutia Therapeutics  (HKSE:02487) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Cutia Therapeutics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutia Therapeutics (HKSE:02487) Business Description

Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.
Executives
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hsg Holding Limited 2201 Interest of corporation controlled by you
Ma Yun 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Aurora Cutis Limited 2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines